婦人科領域での高い抗原性を有する癌胎児抗原 Immunogenic Oncofetal Antigen (OFA-I) の基礎と臨床
スポンサーリンク
概要
- 論文の詳細を見る
A new cancer-related fetal antigen, the immunogenic oncofetal antigen(OFA-I) was discovered during studies on the characterization of membrane of human malignant melanomas by Irie, et al., 1975. The basic and clinical application of OFA-I in hynecologic fields was studied. The results were as follows: 1) Immunochemical and biological characteristics of OFA-I-A. The expression of OFA-I was not dependent on cell cycles by flow cytometric analysis. B. Anti-OFA-I from pregnant women and patients with ovarian cancer specifically reacted with GM2 by immunostaining on TLC plates. C. Anti-OFA-I's failure to function in ADCC was likely explained by antigenic modulation. D. The anti-tumor effects of passively administered anti-OFA-I was demonstrated against a human melanoma cellline,M14,transplanted into athymic nude mice. 2) The significance of OFA-I in normal and abnormal pregnancies-A. A prevalence in anti-OFA-I in sera from pregnant women increased as pregnancy advanced. B. OFA-I was detected in aborted trophoblasts but not normal ones by indirect immunofluorescence and adherence method. C. Of 95 human PBL samples transformed by EBV,only 10 cultures displayed detectable anti-OFA-I activity in the spent medium. Of the 10 cultures,9 ceased to secrete antibody within 2 months. 3) The significance of OFA-I in gynecologic cancers and its clinical application-A. OFA-I was widely distributed in a variety of histologic types of gynecologic malignancies. Tumor OFA-I was highly immunogenic in humans because patients with gynecologic malignancies produced humoral antibody in responses to OFA-I on membranes of melanoma cell lines(M14). B. As to relation of anti-OFA-I profiles to prognosis of patients,we found that the patients in whom anti-OFA-I levels were persistently stable or increased did not develop any recurrences. C. The titer of anti-OFA-I in patients with cervical cancers increased transiently by the injection of live BCG organisms directly into tumor mass. D. OFA-I surface expression was induced by interferon gamma in a variety of OFA-I negative cell lines from gynecologic tumors. 4) Perspectives for clinical application of OFA-I-As a high titer anti-OFA-I may have a direct antitumor effect in vivo,attempts will be made to induce or elevate anti-OFA-I in patients. Two methods will be available: Immunization with OFA-I or OFA-I positive cells(active immunization) and administration of anti-OFA-I antibody(passive immunization).
- 社団法人日本産科婦人科学会の論文
- 1987-08-01
著者
関連論文
- ラIII-6.産婦人科悪性腫瘍における0ncofetal Antigen-I(OFA-I)の組織内分布と腫瘍マーカーとしての意義(免疫細胞化学, ラウンドテープルディスカッション(III), 第28回日本臨床細胞学会総会・学術集会)
- 133. Pituitary hCG like substanceに及ぼす外因性GnRHの効果とその臨床的意義
- 子宮頸部verrucous carcinomaと高分化角化型扁平上皮癌の2例 : 細胞像と組織像
- 194.hCG分泌を示唆するpure Dysgerminoma由来の培養細胞について(婦人科18:基礎(I), 示説, 第25回日本臨床細胞学会秋期大会学術集会)
- 272. ヒト子宮内膜癌および卵巣癌細胞株における組織分化度と HLA抗原について(婦人科11:組織化学, 一般演題示説, 第27回日本臨床細胞学会学術集会)
- 402 絨毛性疾患管理におけるhCG・-βCTP抗体及びβhCGモノクローナル抗体の特異性に関する研究
- 126 自然抗体による体液性免疫能から見た妊娠の生理及び病理
- 90 分化度の異なる子宮内膜癌細胞株の樹立 : allo抗原による組織分化度の分析
- 64. 子宮膣部原発と考えられた悪性黒色腫の1例(示説, 第24回日本臨床細胞学会秋季大会記事)
- 162. Heterologous Membrane Antigenからみた婦人科腫瘍及び正常妊娠における体液性免疫能 : 第29群 免疫 IV